To this aim, we performed a thorough investigation on patients with different tumors of the GI tract, to detect and measure Grp94 expression in both tumor specimens and blood, also testing the response that immune circulating cells of patients might have under the challenge with Grp94. Here, HSP90B1 is linked to neoplasm.